Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster session 01

634P - First results from phase I/II study of CTS2190, a novel small-molecule inhibitor of type I PRMTs, in patients with advanced solid tumors

Date

14 Sep 2024

Session

Poster session 01

Topics

Tumour Site

Gastric Cancer

Presenters

Xiangdong Cheng

Citation

Annals of Oncology (2024) 35 (suppl_2): S482-S535. 10.1016/annonc/annonc1589

Authors

X. Cheng1, Z. Song2, J. Yao3, J. yang3, M. Wang4, H. Zhou5, T. Sun6, Q. Wang7, L. Wu8, J. Miao9, Y. Mi10, J. Lin11, H. Zhao12, S. Xing9, H. Wu10

Author affiliations

  • 1 Department Of Gastric Surgery, Zhejiang Cancer Hospital, 310005 - Hangzhou/CN
  • 2 Phase I Clinical Research Center, Zhejiang Cancer Hospital, 310005 - Hangzhou/CN
  • 3 Department Of Oncology, The First Affiliated Hospital of Henan University of Science and Technology, 471000 - Luoyang/CN
  • 4 Department Of Oncology, The First Affiliated Hospital of Bengbu Medical University, 233004 - Bengbu/CN
  • 5 Phase I Clinical Research Center, The First Affiliated Hospital of Bengbu Medical University, 233004 - Bengbu/CN
  • 6 Department Of Oncology, Cancer Hospital of Dalian University of Technology, Liaoning Cancer Hospital and Institute, 110801 - Shenyang/CN
  • 7 Department Of Oncology, Henan Cancer Hospital, Affiliated Cancer Hospital of Zhengzhou University, 450008 - Zhengzhou/CN
  • 8 Department Of Oncology, Hunan Cancer Hospital, 410013 - Changsha/CN
  • 9 Department Of Clinical Development, CytosinLab Therapeutics Co., Ltd., 201203 - Shanghai/CN
  • 10 Department Of Translational Medicine, CytosinLab Therapeutics Co., Ltd., 311106 - Hangzhou/CN
  • 11 Department Of Oncology, The Second Affiliated Hospital of Kunming Medical University, 650101 - Kunming/CN
  • 12 Department Of Oncology, The First Affiliated Hospital of Xinjiang Medical University, 830054 - Urumqi/CN

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 634P

Background

CTS2190 could specifically inhibit type I protein arginine methyltransferases (PRMTs) and significantly reduce intra-tumor asymmetric dimethylarginine (ADMA) level and oncogenic proliferation by epigenetic modulation, RNA splicing, DNA damage as well as remarkable cancer immune activation in various solid and/or hematological cancers. Here we report the dose escalation results from an ongoing first-in-human phase I/II study to evaluate the safety, tolerability, pharmacokinetics (PK) and efficacy of CTS2190 in patients (pts) with advanced solid tumors.

Methods

Eligible pts were enrolled in escalating dose cohorts (60 to 240 mg) administered orally until progression or unacceptable toxicity. The accelerated titration combined with Bayesian optimal interval (BOIN) design was used as the dose escalation schedule.

Results

As of Apr 2, 2024, 15 pts including 10 non-small cell lung cancer (NSCLC), 1 colorectal cancer (CRC),1 triple-negative breast cancer (TNBC), 2 head and neck squamous cell carcinoma (HNSCC) and 1 esophageal squamous cell carcinoma (ESCC) received CTS2190 treatment. Among them, 9 pts received ≥3 lines of prior therapy. Treatment-related adverse events (TRAEs) of ≥Grade 3 were platelet count decreased (33.3%), amylase increased (6.7%) and blood creatine phosphokinase increased (6.7%). Dose-limiting toxicity (DLT) was observed in 1 pt (in 240 mg) who continued treatment after dose reduction. No TRAEs led to treatment discontinuation or death. Of the 10 response-evaluable pts (>60 mg), the objective response rate (ORR) and disease control rate (DCR) were 20.0% and 70.0% respectively. In the subset of NSCLC pts, the ORR and DCR were 40.0% and 60.0% respectively. Exposure of CTS2190 increased proportionally with increasing dose. Time- and dose-dependent pharmacodynamics (PD) changes in circulating free ADMA, monomethylarginine (MMA) and symmetric dimethylarginine (SDMA) were also observed.

Conclusions

CTS2190 was well tolerated and showed encouraging antitumor activities in advanced and/or metastatic solid tumors, including NSCLC, TNBC, HNSCC and ESCC. Further investigation of CTS2190 in larger pts population is ongoing including biomarker exploration.

Clinical trial identification

NCT06224387.

Editorial acknowledgement

Legal entity responsible for the study

CytosinLab Therapeutics Co., Ltd.

Funding

CytosinLab Therapeutics Co., Ltd.

Disclosure

J. Miao, Y. Mi, S. Xing, H. Wu: Financial Interests, Personal and Institutional, Full or part-time Employment: CytosinLab Therapeutics Co., Ltd. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.